HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones

Lausanne, Switzerland, 03 February 2026, HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, today announced that it has been awarded a grant of CHF 2 million ($2.5 million) by Innosuisse, the Swiss Innovation Agency, to support the preclinical development of its donor-free universal platelets for transfusion.

"This non-dilutive funding further strengthens our financial position and will play a pivotal role in helping us to pursue our mission to address the global shortage of platelets affecting millions of cancer, trauma and surgical patients every year," said Faouzi Khechana, CEO of HemostOD. "Our proprietary platform has the potential to revolutionize blood supply by producing unlimited platelets with improved safety and lower cost. This provides for low clinical risk and ...